AzTrials
AzTrials

ObesityNCT05309057

Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk

An observational study of Obesity and PreDiabetes, run by University of Toronto at 2 sites in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Obesity, PreDiabetes, Diabetes
What is being tested?
Intermittent Fasting
How many people
25 participants
Where
2 sitesCanada
Study dates
1 Nov 2020to Aug 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Adults of all health statuses.

Who may be able to join

  • Randomized controlled trials in humans
  • Intermittent fasting intervention
  • Continuous energy restriction, ad libitum diet, or other intermittent fasting diet as comparators
  • Diet duration ≥1 weeks
  • Data for at least one prespecified outcome
  • Viable outcome data

Who cannot join

  • Non-human studies
  • Observational studies
  • Children
  • Multi-modal interventions
  • Diet duration < 1 weeks
  • No viable outcome data
  • Lack of suitable comparator

Trial locations and contacts

2 sites in 1 country.

Canada2 sites
  • Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital

    Toronto, Ontario, M5C 2T2

  • Faculty of Medicine

    Toronto, Ontario

Other trials in Canada

About this study

Official title: Effect of Intermittent Fasting Strategies on Cardiometabolic Risk: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. There is emerging evidence that intermittent fasting or energy restriction might be more beneficial than continuous energy restriction for some risk factors. The effect of intermittent fasting on risk factors associated with obesity, diabetes, and cardiovascular disease, however, is not clear. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, tthe Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis of randomized controlled trials of the effect of different intermittent fasting strategies on established cardiometabolic risk factors. The findings generated by this proposed knowledge synthesis will shape guide current guidelines and improve health outcomes by educating healthcare providers and patients, and by guiding future research design.

Read the detailed description

Background: 'Intermittent fasting' is currently the most popular trending diet, yet its clinical utility remains unclear. Previous systematic reviews and meta-analyses of intermittent fasting have been limited by a narrow focus on weight loss, one specific method of intermittent fasting, and/or a subset of participants who would be the least likely to benefit. Other issues have included unexplained heterogeneity, incorrect analyses and/or lack of assessment of the certainty of the evidence. There is emerging evidence that intermittent fasting may improve cardiometabolic risk markers independent of calories. However, there is a lack of certainty about the effectiveness of intermittent fasting on overall cardiometabolic risk across different health conditions, and the differences between the various methods of intermittent fasting. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis (an approach which has the advantage over traditional pairwise meta-analyses of being able to assess simultaneously multiple interventions) to assess the effect of the different strategies of intermittent energy restriction (intermittent fasting) versus continuous energy restriction and ad libitum diets on cardiometabolic risk in randomized controlled trials and assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Objective: To assess simultaneously the effect of the various strategies of intermittent energy restriction (intermittent fasting), continuous energy restriction, and ad libitum diets on body weight and other cardiometabolic risk factors in a systematic review and network meta-analysis of randomized trials using the GRADE approach.

Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for network meta-analyses (PRISMA-Network).

Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms. These searches will be supplemented by hand searches of references of included studies. Abstracts will be included and no language restrictions will be used.

Study selection: The investigators will include randomized controlled trials (RCTs) that are >=3-weeks duration investigating the effect of intermittent fasting, continuous caloric restriction and/or ad libitum diets on cardiometabolic risk factors in adults.

Data extraction: Two or more investigators will independently extract relevant data. Standard computations and imputations will be used to derive missing variance data. All disagreements will be resolved by consensus.

Risk of bias: Risk of bias will be assessed using the Cochrane Risk of Bias (RoB) Tool by the two or more investigators.

Outcomes: There will be 10 outcome clusters. The primary outcome will be body weight. Secondary outcomes will be other markers of adiposity (BMI, body fat, waist circumference); glycemic control (glycated blood proteins [HbA1c, fasting blood glucose, postprandial blood glucose, fasting blood insulin, homeostasis model assessment of insulin resistance [HOMA-IR]); established therapeutic lipid targets (LDL-cholesterol, non-HDL-cholesterol, apolipoprotein B [apo B], HDL-cholesterol, triglycerides); blood pressure (systolic blood pressure and diastolic blood pressure); markers of NAFLD (intrahepatocellular lipids [IHCL], alanine aminotransferase [ALT], aspartate aminotransferase [AST]); uric acid; and markers of inflammation (CRP).

Data synthesis: The investigators will perform a network meta-analysis comparing all the interventions simultaneously. These interventions will include alternate day fasting, cyclical whole day fasting, time restricted feeding, continuous energy restriction, and ad libitum diet in a single analysis by combining both direct and indirect evidence across the selected network of studies. Separate pooled analyses will be conducted for each cardiometabolic risk factor using the random-effects network meta-analysis. Intrasitivity will be adjudged using incoherence. Global method of incoherence (design-by-treatment interaction) and inconsistency factors (disagreement between direct and indirect estimates) will be used to estimate incoherence. A-priori subgroup analyses (health status, age, control diet energy restriction, diet supervision, study design, follow-up, feeding control, randomization, energy balance, baseline body weight, funding source, and ROB) will be performed. Separate analysis will be performed in people with diabetes. Publication bias will be assessed if there are ≥10 comparisons. The overall certainty of the evidence for each outcome will be assessed with GRADE using the CINeMA approach.

Evidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant decision makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.

Significance: The proposed project will be the most comprehensive synthesis and evaluation of the totality of evidence on the role of intermittent fasting in cardiometabolic health. These findings will aid in strengthening current guidelines and improve health outcomes by informing shared clinical decision making between healthcare providers and patients and guiding future research.

Being tested
Intermittent Fasting
Keywords
Intermittent fasting, Continuous energy restriction, Weight loss, Systematic review and meta-analysis, Network metanalysis, Randomized controlled trial, Clinical practice guideline, Adiposity, Glycemic control, Blood pressure, Blood lipids, NAFLD markers, Uric acid, inflammatory markers, Cardiometabolic risk factors
Medical subject headings
Obesity, Prediabetic State, Diabetes Mellitus, Hypertension, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Dyslipidemias, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intermittent FastingDietary supplement

    Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.

Study groups in NCT05309057
Study groupRoleWhat they receive
Studies with intermittent fastingStudies with intermittent fasting strategies.
Receives: Dietary Supplement: Intermittent Fasting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body weight

    Body weight in kg

    Measured: Through study completion, up to 20 years

Secondary outcomes (19)
  1. Adiposity - BMI

    Body mass index (BMI) in kg/m2

    Measured: Through study completion, up to 20 years

  2. Adiposity - Waist circumference

    Waist circumference in cm

    Measured: Through study completion, up to 20 years

  3. Adiposity - Body fat

    Body fat in % (relative units)

    Measured: Through study completion, up to 20 years

  4. Glycemic control - HbA1c

    Glycemic control - HbA1c

    Measured: Through study completion, up to 20 years

  5. Glycemic control - fasting plasma glucose (FPG)

    Fasting plasma glucose (FPG) in mmol/L

    Measured: Through study completion, up to 20 years

  6. Glycemic control - 2h plasma glucose (2h-PG)

    2h plasma glucose (2h-PG) during a 75g oral glucose tolerance test (OGTT) in mmol/L

    Measured: Through study completion, up to 20 years

  7. Glycemic control - fasting plasma insulin (FPI)

    Fasting plasma insulin (FPI) in pmol/L

    Measured: Through study completion, up to 20 years

  8. Glycemic control - homeostasis model assessment of insulin resistance (HOMA-IR)

    Homeostasis model assessment of insulin resistance (HOMA-IR)

    Measured: Through study completion, up to 20 years

  9. Established blood lipid targets - LDL-cholesterol (LDL-C)

    LDL-cholesterol (LDL-C) in mmol/L

    Measured: Through study completion, up to 20 years

  10. Established blood lipid targets - non-HDL-cholesterol (non-HDL-C)

    non-HDL-cholesterol (non-HDL-C) in mmol/L

    Measured: Through study completion, up to 20 years

  11. Established blood lipid targets - apolipoprotein B (apo B)

    Apolipoprotein B (apo B) in g/L

    Measured: Through study completion, up to 20 years

  12. Established blood lipid targets - triglycerides

    Triglycerides in mmol/L

    Measured: Through study completion, up to 20 years

  13. Established blood lipid targets - HDL-cholesterol (HDL-C)

    HDL-cholesterol (HDL-C) in mmol/L

    Measured: Through study completion, up to 20 years

  14. Blood pressure - Systolic blood pressure (SBP)

    Systolic blood pressure (SBP) in mmHg

    Measured: Through study completion

  15. Blood pressure - diastolic blood pressure (DBP)

    Diastolic blood pressure (DBP) in mmHg

    Measured: Through study completion, up to 20 years

  16. Markers of non-alcoholic fatty liver disease (NAFLD) - Intrahepatocellular lipids (IHCL)

    Intrahepatocellular lipids (IHCL) in % (relative units)

    Measured: Through study completion, up to 20 years

  17. Markers of non-alcoholic fatty liver disease (NAFLD) - alanine transaminase (ALT)

    Alanine transaminase (ALT) in U/L

    Measured: Through study completion, up to 20 years

  18. Uric acid

    Uric acid in mmol/L

    Measured: Through study completion, up to 20 years

  19. Markers of inflammation - CRP

    CRP in mg/dL

    Measured: Through study completion, up to 20 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2022
  2. Study start1 Nov 2020
  3. Primary completionJun 2022 (estimated)
  4. Study completionAug 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05309057
Sponsor's protocol ID
DNSG-IF
Status last verified
Mar 2022
First submitted
16 Mar 2022
Last updated
4 Apr 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, Chiang N, Oguntala J, Kabisch S, Lau DC, Wharton S, Sharma AM, Harris L, Leiter LA, Hill JO, Hu FB, Lean ME, Kahleova H, Rahelic D, Salas-Salvado J, Kendall CW, Sievenpiper JL. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025 Jun 18;389:e082007. doi: 10.1136/bmj-2024-082007.

    PubMed 40533200

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity and PreDiabetes, run by University of Toronto at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body weight (time frame: Through study completion, up to 20 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05309057, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in